Tag Archive for: biotechnology

ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb’s iPREDICT Phase IIb Study

/in

Los Angeles, California, USA, June 8th, 2022 – ImaginAb Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce that Roche has agreed to provide US approved atezolizumab (Tecentriq®)1, to Non-Small Cell Lung Cancer (NSCLC) patients who are enrolled in ImaginAb’s new Phase IIb […]

Read more

A Q&A with ‘Rising Leader’ Therese Liechtenstein

/in

Therese was selected as one of the top 30 Rising Leaders in the 3rd annual listing of In Vivo’s ‘Rising Leaders’ 2022.

Read more

TargED raises €39 million in a series A investment round

/in

TargED is extremely pleased and proud to have raised €39 million in a Series A investment round! Together with an international investor syndicate  we’ll pursue our common goal: to bring Microlyse into clinical development! Read press release

Read more

Destiny Pharma: Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme

/in

Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme Phase 3 can use similar primary endpoint to the very successful Phase 2b clinical study New European report underpins clinical need and market opportunity of XF-73 Nasal Brighton, United Kingdom, 8 February 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative […]

Read more

ImaginAb Inc. and DongCheng Pharmaceutical Group Announce Plans for a CD8 ImmunoPET Commercial Partnership

/in

Both organizations working together to form a commercial partnership to launch ImaginAb’s CD8 ImmunoPET technology into the Greater China market Los Angeles (USA) and Yantai (China) – January 26th, 2022. ImaginAb, a market leading global biotechnology company, focused on developing next generation immuno-oncology imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce it is working […]

Read more